公开(公告)号：EP2056852A2

公开(公告)日：2009-05-13

申请号：EP07798210.6

申请日：2007-06-07

申请人： Centocor, Inc.

发明人： AMEGADZIE, Bernard ,  CUNNINGHAM, Mark R. ,  DORAI, Haimanti ,  LUO, Jeffrey ,  MILLS, Juliane ,  SWENCKI-UNDERWOOD, Bethany

IPC分类号： A61K38/02 ,  A61P19/00 ,  C07H21/00 ,  C07K2/00 ,  C12N1/00 ,  C12N15/63 ,  C12P21/00

CPC分类号： C07K14/51 ,  A61K38/00

摘要： Human Bone Morphogenic Protein 7 (hBMP-7) variant peptide chains, nucleic acids encoding these peptide chains, and methods of making and using the foregoing are disclosed.

公开(公告)号：EP1622563A4

公开(公告)日：2009-01-14

申请号：EP04711217

申请日：2004-02-13

申请人： ANTIGENICS INC

发明人： FLETCHNER JESSICA ,  PRINCE-COHANE KENYA ,  MEHTA SUNIL ,  SLUSAREWICZ PAUL ,  ANDJELIC SOFIJA ,  BARBER BRIAN H

IPC分类号： A61K39/00 ,  A61K20060101 ,  A61K38/08 ,  A61K38/17 ,  A61K39/385 ,  A61K47/48 ,  A61P35/00 ,  C07K2/00 ,  C07K4/00 ,  C07K7/06 ,  C07K14/47 ,  C07K14/82 ,  C07K19/00

CPC分类号： B82Y5/00 ,  A61K39/0011 ,  A61K39/385 ,  A61K47/646 ,  A61K47/66 ,  A61K2039/6043 ,  A61K2039/622 ,  C07K2319/20

摘要： Hybrid antigens comprising an antigenic domain and improved heat shock protein binding domains are described which are useful for the induction of an immune response to the antigenic domain and thus can be used to treat infectious diseases and cancers that express an antigen of the antigenic domain.

公开(公告)号：EP1888111A4

公开(公告)日：2008-11-19

申请号：EP06772297

申请日：2006-06-06

申请人： AVANT IMMUNOTHERAPEUTICS INC

发明人： ADARI HEDY ,  THOMAS LAWRENCE ,  RITTERHAUS CHARLES W

IPC分类号： A61K39/385 ,  A61K38/00 ,  A61K38/02 ,  A61K38/08 ,  A61K38/16 ,  A61K39/00 ,  C07K2/00 ,  C07K7/04 ,  C07K7/08 ,  C07K14/00 ,  C07K19/00

CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0005 ,  A61K2039/6037 ,  C07K7/08 ,  C07K2319/00

摘要： The present invention relates to autoantigenic vaccine peptides comprising a universal helper T cell epitope portion linked to a B cell epitope portion from the N-terminus of cholesteryl ester transfer protein (CETP). The vaccine peptides are useful for eliciting an autoimmune response in a vaccinated individual, i.e., raising antibodies against the individual's endogenous CETP, in turn modulating circulating CETP activity, reducing LDL-cholesterol levels, and increasing HDL-cholesterol levels, which in turn is helpful to treat cardiovascular disease, such as atherosclerosis.

公开(公告)号：EP1575524A4

公开(公告)日：2008-11-05

申请号：EP03713393

申请日：2003-02-07

申请人： UNIV SOUTH FLORIDA ,  UNIV CHILE

发明人： CAVIEDES PABLO ,  CAVIEDES RAUL ,  FREEMAN THOMAS B ,  SANBERG PAUL R ,  CAMERON DON F

IPC分类号： C12Q1/02 ,  A61K35/12 ,  A61K35/26 ,  A61K45/00 ,  A61P1/16 ,  A61P3/10 ,  A61P5/06 ,  A61P9/10 ,  A61P17/02 ,  A61P19/02 ,  A61P21/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/475 ,  C12N5/00 ,  C12N5/06 ,  A01N1/00 ,  A01N1/02 ,  A01N37/18 ,  A61K38/00 ,  A61K39/00 ,  C07K1/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  G01N33/53

CPC分类号： A61K35/26 ,  C12N5/0018 ,  C12N2500/84 ,  C12N2502/078 ,  C12N2502/30 ,  C12N2503/02

摘要： The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferation cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferation cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.

公开(公告)号：EP1017725B1

公开(公告)日：2008-10-22

申请号：EP98949410.9

申请日：1998-09-18

申请人： InNexus Biotechnology International Ltd

发明人： KOHLER, Heinz

IPC分类号： C07K16/00 ,  C12P21/00 ,  C07K14/47 ,  C07K16/42 ,  A61K47/48 ,  C07K4/00 ,  C07K2/00 ,  C07K1/107 ,  C07K1/13

CPC分类号： C07K14/472 ,  A61K39/00 ,  C07K14/77 ,  C07K16/00 ,  C07K16/4266 ,  C07K2319/00

公开(公告)号：EP1613642A4

公开(公告)日：2008-07-02

申请号：EP04750290

申请日：2004-04-16

申请人： TEXAS A & M UNIV SYS

发明人： BROWN ERIC ,  LEE LAWRENCE ,  HOOK MAGNUS

IPC分类号： C07K1/00 ,  A61K39/00 ,  A61K39/02 ,  A61K39/085 ,  A61K39/38 ,  C07K2/00 ,  C07K14/31 ,  C12N20060101 ,  G01N33/569

CPC分类号： C07K14/31 ,  A61K39/00 ,  A61K2039/505 ,  G01N33/564 ,  G01N33/56938

公开(公告)号：EP1575525A4

公开(公告)日：2008-04-02

申请号：EP03714186

申请日：2003-03-17

申请人： ATTENUON LLC

发明人： MCCRAE KEITH ,  DONATE FERNANDO ,  JUAREZ JOSE ,  MAZAR ANDREW P

IPC分类号： A61K38/00 ,  A61K38/12 ,  A61K38/17 ,  C07K7/64 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  G01N33/68 ,  C07K4/12 ,  C07K2/00 ,  G01N33/53

CPC分类号： G01N33/6887 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4716 ,  C07K16/28 ,  C07K2317/76 ,  G01N2333/4712 ,  G01N2500/02

公开(公告)号：EP1901761A2

公开(公告)日：2008-03-26

申请号：EP06785539.5

申请日：2006-06-23

申请人： Agah, Ramtin

发明人： Agah, Ramtin

IPC分类号： A61K38/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00

CPC分类号： C07K14/78

摘要： Treatments employing the matricellular protein thrombospondin-1 (TSP-I) and related compositions are disclosed for stabilizing atherosclerotic plaque and decreasing occurrence of plaque rupture events leading to, for example, myocardial infarction, stroke, and acute limb ischemia. Various peptides, including certain synthetic peptides, related to TSP-I are also disclosed. Such peptides have utility in stabilizing plaque in various contexts, including the disease states mentioned above. Some of these peptides include one or more sequences related to active sites of TSP-I for regulating, e.g., TGF-βl and MMP-9 activity. Experimental data show that a representative peptide provides a beneficial effect with systemic injection of the peptide.

公开(公告)号：EP1874797A1

公开(公告)日：2008-01-09

申请号：EP06755456.8

申请日：2006-04-27

申请人： Centre National de la Recherche Scientifique ,  Université Montpellier II

发明人： COMMEYRAS, Auguste ,  COLLET, Hélène ,  SOUAID, Eddy ,  COTTET, Hervé ,  ROMESTAN, Bernard ,  TRAMBOUZE, Odile, Yvonne, Marie

IPC分类号： C07K1/00 ,  C07K2/00 ,  A61K47/48 ,  C08G69/00 ,  A01N61/00

CPC分类号： C08G69/10 ,  A01N61/00 ,  C07K14/001 ,  C08G83/003

摘要： The invention relates to the use of monomers of active a-amino acids for the preparation of hydrophobic polypeptides in the form of precipitates, whereby the polypeptides result from the polymerisation of the aforementioned monomers of active a-amino acids in an aqueous solvent and can be resolubilised in said solvent.

公开(公告)号：EP1809651A4

公开(公告)日：2007-10-24

申请号：EP05799165

申请日：2005-10-21

申请人： AUSTRALIAN WOOL INNOVATION LTD

发明人： CRANSTON ROBIN WILLIAM ,  POOLE JACINTA MAREE ,  HICKEY MARK BRENDAN

IPC分类号： C07K1/107 ,  C07K1/14 ,  C07K2/00 ,  C07K14/435 ,  C08H1/06

CPC分类号： C08H1/06 ,  C07K14/4741

摘要： A process for separating keratinous proteins from a keratin-containing material, the process comprising the steps of: subjecting the keratin-containing material to reduction in a liquid medium to solubilise the keratinous proteins under conditions that minimise hydrolysis of the keratinous proteins, to yield a solution of keratinous proteins and undissolved solids; subjecting the solution of keratinous proteins to peroxide oxidation, without any intervening keratin precipitation step; and separating the solution of keratinous proteins from the undissolved solids prior to, at the same time as, or following the oxidation step. Preferred conditions for performing the reduction step involve contacting the keratin-containing material with a solution of an alkali metal sulfide reducing agent at a temperature of between 25 C and 50 C for a time of between 30 and 90 minutes, assuming atmospheric pressure. The peroxide oxidation is suitably carried out within not more than 4 hours after the reduction step, and involves reducing the pH of the solution to a level not less than pH 10, although pH 11.3 is most preferred. The product is demonstrated to have a principal fraction that has a molecular weight above 10 kDa, reflecting that the disulfide bonds in the keratinous proteins are broken without hydrolysis of the proteins.

摘要翻译： 一种从含角蛋白材料分离角质蛋白的方法，该方法包括以下步骤：使含角蛋白材料在液体介质中还原以在角蛋白水解最小化的条件下溶解角蛋白，得到 角质蛋白和不溶解固体的溶液; 使角蛋白溶液经受过氧化物氧化，而不需要任何介入的角蛋白沉淀步骤; 并在氧化步骤之前，同时或之后将角蛋白溶液与不溶解的固体分离。 进行还原步骤的优选条件包括使含角蛋白的材料与碱金属硫化物还原剂的溶液在25℃和50℃之间的温度下接触30-90分钟，假设大气压。 过氧化物氧化适宜在还原步骤后不超过4小时内进行，并且包括将溶液的pH降低至不低于pH10的水平，尽管pH11.3是最优选的。 证明该产物具有分子量高于10kDa的主要部分，这反映出角蛋白中的二硫键被破坏而不会蛋白质水解。